Syndicated
Solutions by APLUSA
AplusA has pioneered the development of syndicated research across numerous therapy areas. Our syndicated studies are designed to provide market insights to multiple clients who purchase a license to access the data and study reports.
Syndicated research at AplusA delivers real-world based insights on a macro or micro level according to your needs. Our expertise in accurately segmenting healthcare markets provides deep, unique datasets and navigate the intricacies of specific markets. Up to 20% of reporting is tailored to the individual client’s requests. Syndicated studies are the solution for marketers interested in maximizing value for money to obtain strategic and actionable insights, while minimizing the pharmacovigilance burden for the pharmaceutical company.
Syndicated
Solutions by APLUSA
AplusA has pioneered the development of syndicated research across numerous therapy areas. Our syndicated studies are designed to provide market insights to multiple clients who purchase a license to access the data and study reports.
Syndicated research at AplusA delivers real-world based insights on a macro or micro level according to your needs. Our expertise in accurately segmenting healthcare markets provides deep, unique datasets and navigate the intricacies of specific markets. Up to 20% of reporting is tailored to the individual client’s requests. Syndicated studies are the solution for marketers interested in maximizing value for money to obtain strategic and actionable insights, while minimizing the pharmacovigilance burden for the pharmaceutical company.
Our syndicated offering is based on real-world data:
- Patient Charts: patients managed by the physician
- Social Media: qualitative and quantitative insights scraped from the web from open data sources
Several purchase options are available:
- Country selection
- Frequency of reporting
- Market segment boost
- Purchase select data only
Why syndicated research?
- Syndicated data collection avoids over-researching small target groups and is cost-efficient
- Our syndicated surveys are based on samples large enough for actionable, country specific findings
- Syndicated research minimizes the AE reporting and compliance burden for the client
Our syndicated offering is based on real-world data:
- Patient Charts: patients managed by the physician
- Social Media: qualitative and quantitative insights scraped from the web from open data sources
Several purchase options are available:
- Country selection
- Frequency of reporting
- Market segment boost
- Purchase select data only
Why syndicated research?
- Syndicated data collection avoids over-researching small target groups and is cost-efficient
- Our syndicated surveys are based on samples large enough for actionable, country specific findings
- Syndicated research minimizes the AE reporting and compliance burden for the client
Hematology & Oncology
- ALL Acute Lymphoblastic Leukemia
- AML Acute Myeloid Leukemia
- Biosimilar vs. Branded in Hematology (Lymphomas DLBCL CLL MCL FL) ; in Inflammation (RA, Pso, CD UC); in Oncology (Breast, NSCLC, CRC)
- CAR-T Therapy
- CLL Chronic lymphocytic Leukemia
- DLBCL
Diffuse Large B-Cell Lymphoma ; Patient records & Social Media - Follicular Lymphoma
- Hemophilia A & B
- MM Multiple Myeloma
- Myelofibrosis
- mRCC Metastatic Renal Cell Carcinoma
Immunology
- Atopic Dermatitis
- Asthma Biologics in Severe Asthma
- Biologic Tracker RA – Pso – UC-Crohn – SPa
- Biosimilar vs. Branded in Hematology (Lymphomas DLBCL CLL MCL FL) ; in Inflammation (RA, Pso, CD UC); in Oncology (Breast, NSCLC, CRC)
- IBD (Inflamatory Bowel Disease) and Crohn’s Disease
- Immunoglobulins in CIDP and MMN Chronic Inflammatory Demyelinating Polyneuropathy and Multifocal Motor Neuropathy
- Sc Immunoglobulins in PID Primary Immunodeficiency
- ITP Immune Thrombocytopenic purpura
- Heart Failure
- PAH Pulmonary Arterial Hypertension
- Migraine
Multiple Myeloma
Syndicated Tracker
This case study outlines the background situation,
AplusA’s approach to the research, and the outcomes for the client.
Let’s talk!
Interested in discovering results from previous waves of one of our syndicated studies, or getting on board for the next one?
Get in touch – we’d be delighted to discuss our syndicated solutions with you.